Skip to content
Medical Health Aged Care

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Clairvoyant Therapeutics 2 mins read

VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.

"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.

"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."

Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.

Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).

About Clairvoyant Therapeutics

Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.

The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.

Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov

-30-

For more information:
Damian Kettlewell
damian@clairvoyantrx.com

SOURCE: Clairvoyant Therapeutics



View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder

More from this category

  • Medical Health Aged Care
  • 26/02/2024
  • 10:55
Arthritis Australia & Monash University

Millennials Face a Painful & Stiff Future – New Report Forecasts Generations Hit Hardest with Arthritis

MEDIA INTERVIEW/FILMING OPPORTUNITY Tuesday 27 February 2024 8.00 – 9.00am New forecasts by researchers at Monash University’s School of Public Health & Preventive Medicine, to be released by Arthritis Australia, reveal millennials are on the front line of a painful and debilitating future health crisis in 2040. It predicts, 1 in 6 millennials will be suffering from arthritis by 2040 as they step into what would be their most productive and fulfilling decades. What aging means for this generation will be redefined as they grapple with the challenges of today’s world and become the generation impacted the most by arthritis…

  • Medical Health Aged Care
  • 26/02/2024
  • 09:00
Dementia Australia

Dementia Australia supports Longreach and Winton

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Longreach and Winton between 11 March to 15 March. It is estimated there are almost 84,000 people living with dementia in Queensland. Without a medical breakthrough this number is expected to increase to more than 168,000 people living with dementia by 2054. These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide. Please…

  • Contains:
  • General News, Medical Health Aged Care
  • 26/02/2024
  • 08:41
MyFitnessPal

DIETICIAN TIPS TO PROTECT YOUR HEART

With heart disease remaining a leading cause of death in Australia, Aussies are being encouraged to reduce their consumption of saturated fats Author and fitness coach Luke Hines provides tips on how to get clued in on saturated fats without compromising on taste Advice follows new research findings from MyFitnessPal that revealed two thirds (64%) of Aussies want to reduce their saturated fat intake With new research highlighting that half of Aussies (50%) are seriously overestimating how much saturated fats can be consumed each day, author, fitness and nutrition coach, Luke Hines has shared his tips on how to make…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.